Your session is about to expire
← Back to Search
Exercise Intervention for Breast Cancer-Related Inflammation (DECODE Trial)
N/A
Recruiting
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adult (≥ 18 years) assigned female sex at birth
Diagnosed with invasive non-metastatic breast cancer
Must not have
Diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global LV contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%
History of prior chemotherapy or targeted H2N Treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up t1 (baseline), t2 (18-40 weeks), and t3 (12-15 months)
Awards & highlights
Summary
This trial is looking at how cancer drugs impact the vascular system and whether or not exercise can help offset some of those changes.
Who is the study for?
This trial is for adults assigned female at birth, diagnosed with non-metastatic breast cancer, receiving certain chemotherapy including anthracyclines or anti-Her2 therapy. Participants must be able to exercise safely and identify as Black/African American or non-Hispanic White. Excluded are those who don't speak English, have metastatic disease, are pregnant/lactating, have cardiovascular disease, prior similar treatments or significant recent weight loss.
What is being tested?
The study tests the 'Taking Charge during Treatment' (TCT) Intervention aimed at understanding how cancer treatment-induced inflammation affects blood vessel function and if exercise can mitigate these effects. It uses advanced -omics technologies to predict microvascular dysfunction from chemotherapy.
What are the potential side effects?
While specific side effects of the TCT Intervention aren't detailed here, potential risks may include typical reactions to moderate exercise and strength training such as muscle soreness or strain.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am an adult woman.
Select...
I have been diagnosed with breast cancer that has not spread.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have heart disease with symptoms or an ejection fraction below 50%.
Select...
I have had chemotherapy or targeted head and neck cancer treatment before.
Select...
I have lost more than 10% of my weight without trying in the last 6 months.
Select...
My cancer has spread to other parts of my body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ t1 (baseline), t2 (18-40 weeks), and t3 (12-15 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~t1 (baseline), t2 (18-40 weeks), and t3 (12-15 months)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Maximal Exercise: Maximal oxygen consumption will be evaluated using cycle ergometry or treadmill to exhaustion as described in the Integrative Physiology Laboratory at each testing visit.
Secondary study objectives
Assess mitochondrial DNA damage
Cardiac function - Echocardiagram
Cardiac function - Pulse Wave Velocity
+12 moreOther study objectives
6 Minute Walk Test
Accelerometry
DEXA Scan
+6 moreTrial Design
2Treatment groups
Active Control
Group I: Taking Charge during Treatment (TCT) InterventionActive Control1 Intervention
Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive "Take Charge" program binder, 2-4 x weekly text messaging, activity tracker and resistance bands.
Group II: Control GroupActive Control1 Intervention
To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the "Take Charge" program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, "take a moment to smile today," a picture of a baby animal).
Find a Location
Who is running the clinical trial?
Medical College of WisconsinLead Sponsor
620 Previous Clinical Trials
1,172,494 Total Patients Enrolled
14 Trials studying Breast Cancer
409,393 Patients Enrolled for Breast Cancer
University of Illinois at ChicagoOTHER
632 Previous Clinical Trials
1,567,635 Total Patients Enrolled
11 Trials studying Breast Cancer
1,342,304 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am undergoing treatment for breast cancer that includes specific chemotherapy drugs or targeted therapy.I have heart disease with symptoms or an ejection fraction below 50%.I am an adult woman.I have had chemotherapy or targeted head and neck cancer treatment before.I have been diagnosed with breast cancer that has not spread.My doctor says I can safely do moderate exercise and strength training.I have lost more than 10% of my weight without trying in the last 6 months.My cancer has spread to other parts of my body.
Research Study Groups:
This trial has the following groups:- Group 1: Taking Charge during Treatment (TCT) Intervention
- Group 2: Control Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger